Scans

Tools

Home

Charts

Watchlist

Products

Max Healthcare Institute Ltd

MAXHEALTH

NSE

₹830.00-1.89%19 Oct 2026

Reports

Hospitals

Max Healthcare Institute Ltd

MAXHEALTH

NSE

₹830.00

-1.89%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Hospitals

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Max Healthcare is India’s second-largest private hospital chain, but it behaves more like a turnaround platform - it buys, builds or takes over hospitals in the country’s richest metro markets, installs a standardised clinical and operational playbook, and pushes each unit towards high-end complex care that commands premium pricing. The company took its current form in 2020 when the healthcare assets of KKR-backed Radiant Life Care were merged with the old Max Healthcare and the combined entity was listed, with Radiant’s promoters - led by turnaround specialist Abhay Soi - taking control. Everything the company does flows from a single recurring idea: concentrate beds in Delhi NCR and Mumbai, where the gap between demand and supply is widest, insurance penetration is deepest, and patients are willing to pay for quaternary care (the most advanced level of treatment), then drive occupancy and pricing by performing procedures that smaller or less-equipped hospitals cannot.

Business segments

A single engine - a network of multi-specialty hospitals in India’s premium metro markets, supported by two small but fast-growing consumer-facing extensions in diagnostics and home healthcare.

1. Hospital network: where the group’s clinical and financial gravity sits

Twenty-one hospitals concentrated in Delhi NCR and Mumbai perform high volumes of complex, high-revenue procedures - transplants, robotic surgeries, cardiac and neuro work - that create a pricing moat few rivals can match.

Metro-first bed placement - roughly 73% of the network’s 6,000-plus beds sit in metro cities, overwhelmingly in Delhi NCR and Mumbai, because those markets have the highest per-capita income, the most insurance coverage, and the greatest willingness to pay for advanced care, which together produce industry-leading revenue per occupied bed.
Complex procedures drive pricing power - the network performs around 2,000 transplants, 8,600 robotic surgeries, 52,900 cardiac procedures, 15,000 neuro surgeries and 14,300 oncology surgeries each year, so the case mix skews towards high-acuity work that justifies an average revenue per occupied bed of ₹78,000.
The payor mix is actively managed - self-pay patients and those covered by third-party administrators or corporates together account for roughly 69% of revenue, while lower-paying institutional beds have been deliberately reduced from 34% of the mix in FY21 because institutional pricing runs about 40-45% below other channels.
International patients fill beds and lift realisations - 15 patient assistance centres across 14 countries, plus tie-ups with foreign ministries of health and overseas doctor OPDs, feed a stream of medical-value travellers that contributed 9% of hospital revenue in the most recent quarter, with some NCR hospitals reaching an 18% international share.
Expansion follows a four-mode playbook with different return profiles - brownfield additions to already-full hospitals can earn returns on capital above 35% because they need few new senior clinicians and ramp up fast; asset-light O&M deals where a developer provides the building can exceed 45% returns; greenfield projects target above 30%; and acquisitions bring immediate beds that are then put through the turnaround process.

2. Max Lab: the diagnostics spoke that reaches patients who never enter a Max hospital

A hub-and-spoke pathology business collects samples from 600-plus collection centres and 830-plus pick-up points across 60 cities, feeding them into 50-plus labs - and it shares revenue with the hospital network rather than competing with it.

Built to scale outside the hospital walls - Max Lab was carved out as a separate subsidiary so it could chase non-captive patients without being constrained by hospital geography, growing from 11 cities and 350 partners to 60-plus cities and 1,500-plus active partners in five years.
Revenue-sharing keeps the network aligned - when a sample is tested in a hospital lab, Max Lab and the hospital split the revenue on an arm’s-length 60:40 basis, so the diagnostics arm expands the total addressable market without cannibalising hospital economics.
Test menu stretches into high-end genomics - the offering spans more than 2,600 routine and specialised tests, including next-generation sequencing, oncology companion diagnostics and haemato-oncology panels, which lets it serve referring clinicians who need more than basic bloodwork.

3. Max@Home: hospital-level care delivered to the living room

One of India’s largest home healthcare providers handles 4,500-plus daily transactions across 16 service lines - from ICU setups and dialysis to physiotherapy and pharmacy - with over half its business coming from repeat patients.

A full ward’s worth of services, mobile - the 16 lines include critical care, nursing, attendants, X-ray, ECG, dialysis, doctor visits, sleep studies and mother-and-child care, so a patient discharged from a Max hospital can continue much of the recovery pathway at home.
Sticky by design - more than 56% of transactions are repeat business, which suggests that once a family uses the service for one episode, it tends to return for the next, reducing the cost of patient acquisition.
Operating in a market that is still largely untapped - home healthcare accounts for only about 3.6% of total health spending in India, compared with roughly 8.3% in the US, so the runway for growth is long before the category reaches saturation.

Group structure and partners

The listed parent sits atop a web of subsidiaries, partner healthcare foundations and O&M contracts that together give it operational control over 21 facilities - but not all the hospitals are owned in the conventional sense.

Partner Healthcare Facilities are a legal wrapper for operational control - three original charitable societies (Balaji, Gujarmal Modi and Devki Devi) own the land and buildings for hospitals in Patparganj, Saket and elsewhere under contracts running to 2064-2105, while Max Healthcare controls medical operations through a Hospital Management Committee and carries significant financial exposure to them, so they are consolidated into network financials even though they are not subsidiaries under accounting rules.
Wholly-owned subsidiaries hold the operating licences - Crosslay Remedies runs the Vaishali and Noida facilities, Hometrail Buildtech runs the two Punjab PPP hospitals, Alps Hospital runs the Gurugram hospital, and Max Hospitals and Allied Services operates the Nanavati hospital in Mumbai under a 29-year O&M agreement with a right of first refusal at expiry.
Asset-light O&M deals are expanding the footprint without the land cost - the Dwarka hospital runs under an O&M agreement with Muthoot Hospitals, while built-to-suit leases are signed for upcoming hospitals in Mohali, Thane and Dehradun, where a developer provides the shell and Max Healthcare provides the clinical operations.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹80,785Cr

Close Price

₹830.00

Industry

Hospitals

Price To Earnings

55.37

Price To Sales

9.27

Revenue

₹8,712Cr

Rev Gr TTM

Revenue Growth TTM

15.96%

PAT Gr TTM

PAT Growth TTM

27.00%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	1,363	1,335	1,423	1,543	1,707	1,868	1,910	2,028	2,135	2,068	2,143	2,366
Growth YoY Revenue Growth YoY%	19.9	16.9	17.2	20.1	25.3	40.0	34.2	31.4	25.1	10.7	12.2	16.7
Expenses ExpensesCr	976	949	1,041	1,156	1,257	1,369	1,398	1,505	1,560	1,529	1,536	1,768
Operating Profit Operating ProfitCr	387	386	382	387	451	499	512	523	575	538	606	598
OPM OPM%	28.4	28.9	26.8	25.1	26.4	26.7	26.8	25.8	26.9	26.0	28.3	25.3
Other Income Other IncomeCr	45	46	45	35	41	-40	47	37	33	-3	48	41
Interest Expense Interest ExpenseCr	9	11	21	24	34	52	55	55	54	60	67	71
Depreciation DepreciationCr	58	61	70	77	84	98	101	104	108	111	123	132
PBT PBTCr	366	360	336	321	374	309	403	400	446	365	465	436
Tax TaxCr	90	70	84	85	92	70	84	92	-45	64	122	113
PAT PATCr	277	289	252	236	282	239	319	308	491	301	342	323
Growth YoY PAT Growth YoY%	-39.5	30.1	0.3	-1.6	1.9	-17.5	26.8	30.4	74.3	26.0	7.3	4.9
NPM NPM%	20.3	21.7	17.7	15.3	16.5	12.8	16.7	15.2	23.0	14.6	16.0	13.7
EPS EPS₹	2.9	3.0	2.6	2.4	2.9	2.5	3.3	3.2	5.0	3.1	3.5	3.3

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	1,363	1,335	1,423	1,543	1,707	1,868	1,910	2,028	2,135	2,068	2,143	2,366
Growth YoY Revenue Growth YoY%	19.9	16.9	17.2	20.1	25.3	40.0	34.2	31.4	25.1	10.7	12.2	16.7
Expenses ExpensesCr	976	949	1,041	1,156	1,257	1,369	1,398	1,505	1,560	1,529	1,536	1,768
Operating Profit Operating ProfitCr	387	386	382	387	451	499	512	523	575	538	606	598
OPM OPM%	28.4	28.9	26.8	25.1	26.4	26.7	26.8	25.8	26.9	26.0	28.3	25.3
Other Income Other IncomeCr	45	46	45	35	41	-40	47	37	33	-3	48	41
Interest Expense Interest ExpenseCr	9	11	21	24	34	52	55	55	54	60	67	71
Depreciation DepreciationCr	58	61	70	77	84	98	101	104	108	111	123	132
PBT PBTCr	366	360	336	321	374	309	403	400	446	365	465	436
Tax TaxCr	90	70	84	85	92	70	84	92	-45	64	122	113
PAT PATCr	277	289	252	236	282	239	319	308	491	301	342	323
Growth YoY PAT Growth YoY%	-39.5	30.1	0.3	-1.6	1.9	-17.5	26.8	30.4	74.3	26.0	7.3	4.9
NPM NPM%	20.3	21.7	17.7	15.3	16.5	12.8	16.7	15.2	23.0	14.6	16.0	13.7
EPS EPS₹	2.9	3.0	2.6	2.4	2.9	2.5	3.3	3.2	5.0	3.1	3.5	3.3

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	1,445	1,608	1,729	1,691	1,059	2,505	3,937	4,563	5,406	7,028	8,373	8,712
Growth Revenue Growth%	27.5	11.3	7.5	-2.2	-37.4	136.5	57.2	15.9	18.5	30.0	19.1	16.0
Expenses ExpensesCr	1,330	1,468	1,616	1,536	965	2,101	2,989	3,322	3,913	5,180	6,131	6,394
Operating Profit Operating ProfitCr	116	140	113	155	94	404	948	1,241	1,493	1,849	2,243	2,318
OPM OPM%	8.0	8.7	6.5	9.2	8.8	16.1	24.1	27.2	27.6	26.3	26.8	26.6
Other Income Other IncomeCr	30	42	54	57	48	-119	113	139	177	82	114	118
Interest Expense Interest ExpenseCr	73	100	99	101	83	179	101	84	60	165	235	251
Depreciation DepreciationCr	87	96	94	103	46	174	221	232	245	359	447	474
PBT PBTCr	-14	-12	-26	8	13	-69	739	1,064	1,365	1,406	1,676	1,711
Tax TaxCr	0	-11	10	9	0	46	134	-40	308	330	233	254
PAT PATCr	-14	-1	-36	0	13	-115	605	1,104	1,058	1,076	1,442	1,457
Growth PAT Growth%	61.5	90.2	-2,502.9	99.5	6,894.7	-986.9	628.4	82.4	-4.2	1.7	34.1	27.0
NPM NPM%	-1.0	-0.1	-2.1	0.0	1.2	-4.6	15.4	24.2	19.6	15.3	17.2	16.7
EPS EPS₹	-0.3	0.3	-0.5	-0.1	1.0	-1.6	6.3	11.4	10.9	11.1	14.8	15.0

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	1,445	1,608	1,729	1,691	1,059	2,505	3,937	4,563	5,406	7,028	8,373	8,712
Growth Revenue Growth%	27.5	11.3	7.5	-2.2	-37.4	136.5	57.2	15.9	18.5	30.0	19.1	16.0
Expenses ExpensesCr	1,330	1,468	1,616	1,536	965	2,101	2,989	3,322	3,913	5,180	6,131	6,394
Operating Profit Operating ProfitCr	116	140	113	155	94	404	948	1,241	1,493	1,849	2,243	2,318
OPM OPM%	8.0	8.7	6.5	9.2	8.8	16.1	24.1	27.2	27.6	26.3	26.8	26.6
Other Income Other IncomeCr	30	42	54	57	48	-119	113	139	177	82	114	118
Interest Expense Interest ExpenseCr	73	100	99	101	83	179	101	84	60	165	235	251
Depreciation DepreciationCr	87	96	94	103	46	174	221	232	245	359	447	474
PBT PBTCr	-14	-12	-26	8	13	-69	739	1,064	1,365	1,406	1,676	1,711
Tax TaxCr	0	-11	10	9	0	46	134	-40	308	330	233	254
PAT PATCr	-14	-1	-36	0	13	-115	605	1,104	1,058	1,076	1,442	1,457
Growth PAT Growth%	61.5	90.2	-2,502.9	99.5	6,894.7	-986.9	628.4	82.4	-4.2	1.7	34.1	27.0
NPM NPM%	-1.0	-0.1	-2.1	0.0	1.2	-4.6	15.4	24.2	19.6	15.3	17.2	16.7
EPS EPS₹	-0.3	0.3	-0.5	-0.1	1.0	-1.6	6.3	11.4	10.9	11.1	14.8	15.0

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	533	537	537	537	537	966	970	971	972	972	973
Reserves ReservesCr	587	655	627	426	2,016	4,673	5,313	6,439	7,436	8,409	9,771
Current Liabilities Current LiabilitiesCr	419	381	477	1,140	1,010	777	757	1,046	1,249	1,806	2,187
Non Current Liabilities Non Current LiabilitiesCr	672	1,660	1,806	1,262	411	2,129	2,149	1,647	2,343	4,027	4,297
Total Liabilities Total LiabilitiesCr	2,217	3,160	3,314	3,366	3,974	8,544	9,189	10,102	12,000	15,214	17,231
Current Assets Current AssetsCr	289	349	454	447	2,915	1,124	1,000	1,943	1,706	1,593	1,945
Non Current Assets Non Current AssetsCr	1,928	2,811	2,860	2,918	1,058	7,420	8,189	8,159	10,294	13,622	15,286
Total Assets Total AssetsCr	2,217	3,160	3,314	3,366	3,974	8,544	9,189	10,102	12,000	15,214	17,231

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	533	537	537	537	537	966	970	971	972	972	973
Reserves ReservesCr	587	655	627	426	2,016	4,673	5,313	6,439	7,436	8,409	9,771
Current Liabilities Current LiabilitiesCr	419	381	477	1,140	1,010	777	757	1,046	1,249	1,806	2,187
Non Current Liabilities Non Current LiabilitiesCr	672	1,660	1,806	1,262	411	2,129	2,149	1,647	2,343	4,027	4,297
Total Liabilities Total LiabilitiesCr	2,217	3,160	3,314	3,366	3,974	8,544	9,189	10,102	12,000	15,214	17,231
Current Assets Current AssetsCr	289	349	454	447	2,915	1,124	1,000	1,943	1,706	1,593	1,945
Non Current Assets Non Current AssetsCr	1,928	2,811	2,860	2,918	1,058	7,420	8,189	8,159	10,294	13,622	15,286
Total Assets Total AssetsCr	2,217	3,160	3,314	3,366	3,974	8,544	9,189	10,102	12,000	15,214	17,231

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	723	156	166	89	77	118	741	1,209	1,122	1,438	1,633
Investing Cash Flow Investing Cash FlowCr	-1,340	-104	-124	-17	-2,641	-73	-764	-1,187	-1,285	-1,611	-1,689
Financing Cash Flow Financing Cash FlowCr	603	-48	-48	-74	2,353	191	-294	-289	-264	-163	59
Net Cash Flow Net Cash FlowCr	-14	4	-6	-2	-210	236	-317	-266	-428	-336	4
Free Cash Flow Free Cash FlowCr	-880	41	100	-27	-13	1	192	877	342	500	165
CFO To PAT CFO To PAT%	-5,063.1	-11,147.1	-454.8	-46,815.8	597.1	-102.9	122.4	109.6	106.0	133.7	113.2
CFO To EBITDA CFO To EBITDA%	625.0	111.2	146.3	57.3	82.4	29.2	78.1	97.5	75.1	77.8	72.8

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	723	156	166	89	77	118	741	1,209	1,122	1,438	1,633
Investing Cash Flow Investing Cash FlowCr	-1,340	-104	-124	-17	-2,641	-73	-764	-1,187	-1,285	-1,611	-1,689
Financing Cash Flow Financing Cash FlowCr	603	-48	-48	-74	2,353	191	-294	-289	-264	-163	59
Net Cash Flow Net Cash FlowCr	-14	4	-6	-2	-210	236	-317	-266	-428	-336	4
Free Cash Flow Free Cash FlowCr	-880	41	100	-27	-13	1	192	877	342	500	165
CFO To PAT CFO To PAT%	-5,063.1	-11,147.1	-454.8	-46,815.8	597.1	-102.9	122.4	109.6	106.0	133.7	113.2
CFO To EBITDA CFO To EBITDA%	625.0	111.2	146.3	57.3	82.4	29.2	78.1	97.5	75.1	77.8	72.8

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr						19,903	33,636	42,818	79,736	1,06,615	93,582	80,785
Price To Earnings Price To Earnings							55.6	38.8	75.4	99.1	64.9	55.4
Price To Sales Price To Sales						7.9	8.1	8.9	14.8	15.2	11.2	9.3
Price To Book Price To Book						3.5	5.3	5.8	9.5	11.4	8.7	7.5
EV To EBITDA EV To EBITDA						50.3	35.9	33.9	53.5	58.9	43.0	36.7
Profitability Ratios Profitability Ratios
GPM GPM%	65.8	69.0	69.5	49.0	48.3	49.5	51.4	53.7	54.4	53.2	52.6	52.6
OPM OPM%	8.0	8.7	6.5	9.2	8.8	16.1	24.1	27.2	27.6	26.3	26.8	26.6
NPM NPM%	-1.0	-0.1	-2.1	0.0	1.2	-4.6	15.4	24.2	19.6	15.3	17.2	16.7
ROCE ROCE%	3.1	4.3	3.4	5.7	2.8	1.6	11.7	14.2	14.7	12.7	13.4	13.4
ROE ROE%	-1.3	-0.1	-3.1	0.0	0.5	-2.0	9.6	14.9	12.6	11.5	13.4	13.4
ROA ROA%	-0.6	0.0	-1.1	0.0	0.3	-1.3	6.6	10.9	8.8	7.1	8.4	8.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr						19,903	33,636	42,818	79,736	1,06,615	93,582	80,785
Price To Earnings Price To Earnings							55.6	38.8	75.4	99.1	64.9	55.4
Price To Sales Price To Sales						7.9	8.1	8.9	14.8	15.2	11.2	9.3
Price To Book Price To Book						3.5	5.3	5.8	9.5	11.4	8.7	7.5
EV To EBITDA EV To EBITDA						50.3	35.9	33.9	53.5	58.9	43.0	36.7
Profitability Ratios Profitability Ratios
GPM GPM%	65.8	69.0	69.5	49.0	48.3	49.5	51.4	53.7	54.4	53.2	52.6	52.6
OPM OPM%	8.0	8.7	6.5	9.2	8.8	16.1	24.1	27.2	27.6	26.3	26.8	26.6
NPM NPM%	-1.0	-0.1	-2.1	0.0	1.2	-4.6	15.4	24.2	19.6	15.3	17.2	16.7
ROCE ROCE%	3.1	4.3	3.4	5.7	2.8	1.6	11.7	14.2	14.7	12.7	13.4	13.4
ROE ROE%	-1.3	-0.1	-3.1	0.0	0.5	-2.0	9.6	14.9	12.6	11.5	13.4	13.4
ROA ROA%	-0.6	0.0	-1.1	0.0	0.3	-1.3	6.6	10.9	8.8	7.1	8.4	8.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,10,714	82,875	80,785	58,154	55,701	35,577	33,289
Close PriceClose₹	7,700.00	630.05	830.00	667.15	737.80	1,740.90	1,238.10
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.98	88.37	55.37	107.95	53.16	43.33	59.81
Price To SalesPS	4.19	8.02	9.27	11.93	5.86	3.92	7.11
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,10,714	82,875	80,785	58,154	55,701	35,577	33,289
Close PriceClose₹	7,700.00	630.05	830.00	667.15	737.80	1,740.90	1,238.10
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.98	88.37	55.37	107.95	53.16	43.33	59.81
Price To SalesPS	4.19	8.02	9.27	11.93	5.86	3.92	7.11
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26